Benfotiamine

Vitaminwater-solubleStrong dose evidence

Also known as: S-benzoylthiamine O-monophosphate, BTMP, lipid-soluble thiamin, fat-soluble B1

Add to a formula

Benfotiamine is a synthetic, lipid-soluble derivative of thiamin that is converted to thiamin in the body. Its structure lets it bypass the saturable transporter that limits ordinary thiamin uptake, so higher tissue thiamin levels are reached per milligram. It has been studied mostly in people with type 2 diabetes for nerve comfort and blood-sugar-related pathways, with randomized trials using 120 to 900 mg per day. It is a specialty B1 used in nerve-support, glucose-support, and healthy-aging formulas rather than in basic multivitamins.

Research summary

Dephosphorylated and absorbed as the lipophilic S-benzoylthiamine, then converted to thiamin and thiamin diphosphate; raises transketolase activity, which diverts glycolytic intermediates away from advanced glycation end-product formation.

Dosage

Daily amounts, of compound.

Lowest studiedTypical rangeHighest studiedUpper limit
150 mg150–600 mg900 mg

Doses are mg benfotiamine. NIH ODS summarizes small randomized studies using 120 to 900 mg/day. The BOND trial (Ziegler 2026) used 300 mg twice daily (600 mg) for 12 months in type 2 diabetes with polyneuropathy; the earlier BEDIP pilot used 400 mg/day (50 mg tablets, two four times daily) for 3 weeks. Typically split into two or three doses with meals. No UL has been set for thiamin or its derivatives. Note that benfotiamine is not labeled as thiamin for DV purposes.

Standardization: ≥98% benfotiamine

Source material: synthetic

Forms of Thiamin (Vitamin B1)

FormTypical doseElement %FormatsPrice
Benfotiamine150–600 mgCapsule, Tablet, Powdermid
Thiamin HCl (Vitamin B1)1.5–100 mgCapsule, Powder, Tablet, Gummy, Liquidlow

Format suitability

  • Capsule
  • Powder
  • Tablet
  • Softgel
  • Gummy
  • Liquid

Neutral taste; fine in capsules and tablets. Rarely used in gummies or liquids.

Formulation notes

Often stacked with alpha-lipoic acid, methylcobalamin, and pyridoxal-5-phosphate in nerve-support formulas.

Sources

  1. Thiamin — Health Professional Fact SheetNIH ODS
  2. Effects of benfotiamine treatment over 12 months on morphometric, neurophysiological and clinical measures in type 2 diabetes patients with symptomatic polyneuropathy: a randomized, placebo-controlled, double-blind clinical trial (BOND study). (Ziegler D, 2026)PubMed
  3. Benfotiamine in the treatment of diabetic polyneuropathy--a three-week randomized, controlled pilot study (BEDIP study). (Haupt E, 2005)PubMed

Related ingredients